Literature DB >> 8335744

Large keratoacanthomas treated with intralesional interferon alfa-2a.

J J Grob1, F Suzini, M A Richard, M Weiller, H Zarour, C Noe, M H Munoz, J J Bonerandi.   

Abstract

BACKGROUND: Spontaneous involution of giant keratoacanthomas (KAs) can leave large scars or cause mutilation. Human papillomaviruses have recently been demonstrated in KAs. Intralesional interferon alfa-2a (IFN alfa-2a) has been shown to have activity against different epithelial tumors and to have an antiviral effect.
OBJECTIVE: This study was conducted to determine whether it was possible to stop extension of large KAs, to accelerate healing, and to obtain good cosmetic results with intralesional IFN alfa-2a.
METHODS: Six large KAs were treated with intralesional IFN alfa-2a.
RESULTS: Regression was obtained in five cases in 3 to 7 weeks with excellent cosmetic results. The main side effect was pain during injection.
CONCLUSION: Our results suggest that this treatment hastens healing and limits scarring.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335744     DOI: 10.1016/0190-9622(93)70174-r

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  3 in total

1.  Giant keratoacanthoma of the upper extremity treated with mohs micrographic surgery: a case report and review of current treatment modalities.

Authors:  Jorge Garcia-Zuazaga; Malcolm Ke; Patrick Lee
Journal:  J Clin Aesthet Dermatol       Date:  2009-08

2.  The Effectiveness of Cryosurgery Combined with Curettage and Electrodessication in the Treatment of Keratoacanthoma: A Retrospective Analysis of 90 Cases.

Authors:  Antonios Panagiotopoulos; Nikolaos Kyriazis; Eleni Polychronaki; George D Leotsakos; Polytimos Vassis; Dimitrios Rigopoulos
Journal:  Indian J Dermatol       Date:  2020 Sep-Oct       Impact factor: 1.494

Review 3.  Intratumoural administration and tumour tissue targeting of cancer immunotherapies.

Authors:  Ignacio Melero; Eduardo Castanon; Maite Alvarez; Stephane Champiat; Aurelien Marabelle
Journal:  Nat Rev Clin Oncol       Date:  2021-05-18       Impact factor: 66.675

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.